SlideShare a Scribd company logo
D . B A S E M E L S A I D E N A N Y
L E C T U R E R O F C A R D I O L O G Y
A I N S H A M S U N I V E R S I T Y
Resistant Hypertension:
Treatment
Resistant hypertension
--Definition:
2008 American Heart Association guideline  blood
pressure that remains above goal in spite of concurrent
use of three antihypertensive agents of different
classes, one of which should be a diuretic. Patients
whose blood pressure is controlled with four or more
medications are considered to have resistant
hypertension (20-30%).
Treatment of resistant hypertension
1-Identify and treat secondary hypertension.
2-Stop medications that raise the blood pressure (next
slide).
3-Out-of-office BP monitoring:
Apparently resistant patients should be evaluated by out-of
office blood pressure measurements, either by self
measurement of blood pressure at home or by ambulatory
monitoring. Both home and ambulatory blood pressure
measurements help to identify white coat hypertension.
4-NONPHARMACOLOGIC THERAPY
5-PHARMACOLOGIC THERAPY
- Nonnarcotic analgesics
- Nonsteroidal antiinflammatory agents, including aspirin
- Selective COX-2 inhibitors
- Sympathomimetic agents (decongestants, diet pills, cocaine)
- Stimulants
(methylphenidate, dexmethylphenidate, dextroamphetamine, a
mphetamine, methamphetamine,
modafinil)
- Alcohol
- Oral contraceptives
- Cyclosporine
- Erythropoietin
- Natural licorice
- Herbal compounds (ephedra or ma huang)
Diuretics
--Persistent volume expansion (typically not sufficient to produce
edema) contributes to resistant hypertension, even among patients
who have been on conventional doses of thiazide diuretics. Serum
brain-type natriuretic peptide and atrial natriuretic peptide levels are
significantly higher, suggesting volume expansion.
--Diuretics should be titrated until the blood pressure goal or the
maximum recommended dose has been reached or the patient has
signs suggestive of overdiuresis such as fatigue, orthostatic
hypotension, or decreased tissue perfusion as evidenced by an
otherwise unexplained elevation in the serum creatinine
concentration.
--In those with little renal impairment, chlorthalidone is preferred to
hydrochlorothiazide for the treatment of resistant hypertension.
--Begin chlorthalidone at 12.5 mg daily, which requires splitting of the
25 mg pill, with subsequent titration up to 25 mg daily
or, rarely, higher. {serum K}
--Among patients with an estimated glomerular
filtration rate of less than 30 mL/min per m2, thiazide
diuretics are less effective and loop diuretics, such as
furosemide, torsemide, or bumetanide, may be
necessary for effective volume control. Furosemide is
relatively short acting and usually requires at least
twice daily dosing. A loop diuretic with a longer
duration of action and more consistent
absorption, such as torsemide, may be more effective
Aldosterone antagonists
--Spironolactone, eplerenone, and amiloride provide
significant antihypertensive benefit when added to
existing multiple drug regimens in patients with
resistant hypertension .{significantly higher plasma
aldosterone levels in patients with resistant
hypertension compared with individuals who have
normal blood pressure or controlled hypertension }
--Spironolactone may be more likely to cause
hyperkalemia in patients with chronic kidney disease .
CHOICE OF REGIMEN
--The triple combination of an ACE inhibitor or ARB, a long-
acting dihydropyridine calcium channel blocker (usually
amlodipine), and a long-acting thiazide diuretic (preferably
chlorthalidone) is often effective and generally well tolerated.
--Uncontrolled with such a three drug regimen at maximum
recommended and tolerated doses spironolactone: 12.5
mg/day (which requires splitting of a 25 mg tablet) before
titrating to 25 and, if necessary, 50 mg/day.
The risk of adverse effects such as gynecomastia, breast
tenderness, and erectile dysfunction increases with higher
doses.
[eplerenone, is now generic and does not induce the side effects
seen with spironolactone]
--Some patients with resistant hypertension are being treated with a three
drug regimen different:
If the patient is on hydrochlorothiazide, switch to chlorthalidone.
If the current regimen includes a drug not from the three recommended drug
classes, add the missing preferred drug and assess the response. Do not
discontinue any drugs, as long as they are well tolerated, before achieving
blood pressure control.
--If the patient is still hypertensive, additional medications are added
sequentially. Possible agents that may be used include vasodilating beta
blockers (labetalol, carvedilol, or nebivolol), centrally acting agents (clonidine
or guanfacine)[may be effective, but adverse effects are common], and direct
vasodilators (hydralazine or minoxidil) [Fluid retention and tachycardia are
common side effects. Minoxidil also causes hirsutism, which may be a
particular problem in women that may require switching to
hydralazine(lupus
like=withdrawal, nausea, vomiting, flushing,tachycardia), and pericarditis].
Catheter-based radiofrequency ablation of renal
sympathetic nerves
The mechanism by which renal sympathetic
denervation improves management of BP is complex
and involves the following factors:
-Decreasing efferent sympathetic signaling to kidneys
-Reducing norepinephrine spillover
-Natriuresis
-Increasing renal blood flow
-Lowering plasma rennin activity
-Decreasing renal afferent signalling and central
sympathetic activation
Indications
--Refractory hypertension with office SBP >160 mmHg
despite treatment with the least 3 antihypertensive
medications including diuretic in optimal doses.
--Exclusion of secondary forms of hypertension.
--Exclusion of “white coat” hypertension using
ambulatory blood pressure monitoring.
SYMPLICITY HTN-3: Renal Denervation Fails to
Reduce BP in Resistant-Hypertension Patients
Led by Dr Deepak Bhatt (Brigham and Women's
Hospital, Boston, MA) and Dr George Bakris (University
of Chicago, IL), SYMPLICITY HTN-3 is a
randomized, sham-controlled renal-denervation study in
535 patients with severe resistant hypertension. After six
months, the mean change in systolic blood pressure was a
reduction of 14.13 mm Hg in the renal-denervation arm
and 11.74 mm Hg in the sham-controlled arm, a difference
of 2.39 mm Hg that was not statistically significant.
Regarding the change in the 24-hour ambulatory systolic
blood pressure, the reduction at six months was 6.75 mm
Hg in the renal-denervation arm and 4.79 mm Hg in the
control arm, a difference of 1.96 mm Hg that was also not
statistically
For anyone who participates in clinical trials, the oversight of a clinical
trial is such that the patients are very rigorously followed, and there is
pill-counting and recommendations for strict compliance, all of which
is very different from what happens with "optimal medical therapy" in
real-world practice.
Furthermore, this was a renal denervation strategy with a particular
device, so it could be that this particular device isn't the best device for
renal denervation.
A third practical question, which is unanswered, is whether we really
achieved renal denervation. The animal and preclinical trials looked at
how much energy was needed to create an injury that went from the
renal artery lumen down to the renal nerves. Perhaps in this middle-
aged group of patients with hypertension on a western diet, there is
greater thickening of the renal vessel, which could actually cause
problems in delivering the energy required to achieve effective renal
denervation.
Contraindications
--Increased bleeding risk (bleeding
diathesis, thrombocytopenia, severe anemia)
--Chronic renal disease
--eGFR < 45 mL/min/1.73m2
--Type 1 diabetes
--Previous renal artery intervention (angioplasty, stent
implantation)
--Anatomic abnormalities and variants of renal artery
including aneurysms, severe stenosis, reference diameter
<4 mm, excessive tortuosity, aortic aneurysm
--Age < 18 years
--Pregnancy
Technique
--Vascular access is similar to renal angiography and angioplasty.
--Current 5F system uses 6F guide catheters. After engaging the renal
artery, and angiography to evaluate the anatomy of the renal
arteries, the ablation catheter is placed under fluoroscopic guidance in
the distal segment of the renal artery.
--Each RF application is followed by retraction by at least 5 mm and
rotation by 90 degrees of the catheter tip, from the first distal main
renal artery bifurcation to the ostium.
--To achieve complete denervation, multiple (4-6) RF applications are
used depending on the length of the trunk of both renal arteries. This
approach provides circumferential disruption of sympathetic nerves.
--The procedure is performed under analgetic or conscious sedation to
lessen the pain
Symplicity Catheter System Design (Medtronic Vascular)
**Procedure-related complications are:
-Access site complication
(hematoma, pseudoaneurysm, dissection)
-Renal artery dissection
-Progression of a pre-existing renal artery stenosis
-Regeneration of efferent nerves leading to relapse of
resistant hypertension
-Bradycardia
--Was tested in the Symplicity-HTN-2 trial of 106 patients with
resistant hypertension despite treatment with an average of five
antihypertensive medications including a diuretic.
--The patients were randomly assigned to renal sympathetic
denervation or maintenance of previous medical therapy.
--At six months, radiofrequency ablation significantly decreased the
office blood pressure from 178/97 to 143/85 mmHg compared with no
decrease in blood pressure in patients maintained on baseline
antihypertensive therapy.
--In addition, a systolic pressure of less than 140 mmHg was attained
significantly more often with radiofrequency ablation (39 versus 6 %).
--There was no significant difference between the groups in kidney
function. Complications related to radiofrequency ablation included
one femoral artery pseudoaneurysm.
--Long-term data regarding efficacy and safety of radiofrequency
ablation remain limited.
Possible indications
1-Sleep apnea:
The mechanism of such effect of renal denervation of sleep
apnea is unknown, however the influence on sodium retention
and volemic status is likely to be involved.
2-Insulin Resistance/type 2 diabetes mellitus:
The beneficial effects on glucose metabolism may be explained
by several effects of renal denervation: inhibition of central
sympathetic tone, reduced release of norepinephrine, better
perfusion of skeletal muscles mediated via a decrease of alpha-
adrenergic tone leading to increased glucose uptake.
3-Congestive Heart Failure:
Increased sympathetic activity is present in patients with heart
failure and it is correlated with functional class.
Electrical stimulation of carotid sinus
baroreceptors
--Electrical stimulation of the carotid sinus baroreflex
system, or baroreflex activation therapy (BAT), may
decrease blood pressure in patients with resistant
hypertension.
--Three feasibility studies have shown reductions in
blood pressure after implantation of a device designed
to stimulate the carotid baroreflex system .
*In the Rheos Pivotal Trial, 265 patients with resistant hypertension underwent
surgical implantation of a device designed to stimulate the carotid baroreceptors.
One month after surgery, patients were randomly assigned to have BAT turned on
immediately or to have BAT turned on six months later. The patients were followed for
at least 12 months:
--At six months, patients receiving BAT had a nonsignificantly larger decrease in
systolic pressure (16 versus 9 mmHg) and a nonsignificantly greater likelihood of
having a 10 mmHg or larger decrease in systolic pressure (54 versus 46 %). In
addition, patients receiving BAT were significantly more likely to achieve a goal systolic
pressure of 140 mmHg or lower (42 versus 24 %).
--At twelve months, the mean reduction in systolic pressure in the BAT group was 25
mmHg; more than 80 % of these patients had at least a 10 mmHg decrease in systolic
pressure.
--Within one month of surgery, 35 % of patients had a serious procedure-related
adverse event, including nerve injury. In most patients, procedure-related adverse
events resolved spontaneously. Seven patients died (3 %), but none were
attributable to the device.
*Malignant hypertension:
--Refers to marked hypertension with retinal
hemorrhages, exudates, or papilledema. These findings may be
associated with hypertensive encephalopathy{cerebral oedema}.
--Usually associated with BP>180/120 mmHg. However, it can occur
at diastolic pressures as low as 100 mmHg in previously normotensive
patients with acute hypertension due to preeclampsia or acute
glomerulonephritis.
*Hypertensive urgency:
--Severe hypertension (as defined by a diastolic blood pressure above
120 mmHg) in asymptomatic patients.
--There is no proven benefit from rapid reduction in BP in
asymptomatic patients who have no evidence of acute end-organ
damage and are at little short-term risk.
Hypertensive urgencies
*BP>180/120mmHg, no symptoms apart from headache.
*A relatively rapid reduction in blood pressure (BP) was
recommended in the past. However, in the absence of
symptoms a more gradual reduction in pressure is
suggested.
*While a variety of oral therapeutic modalities have been
used, including clonidine, sublingual nifedipine, and oral
or sublingual captopril, sublingual nifedipine is now
contraindicated in this setting {blood pressure falls below
the range at which tissue perfusion can be maintained by
autoregulation}.
*All patients should be provided a quiet room to rest; this can lead to a fall in
BP of 10 to 20 mmHg or more.
*Previously treated hypertension:
--Increase the dose of existing antihypertensive medications, or add another
agent.
--Reinstitution of medications in non-adherent patients.
--Addition of a diuretic, and reinforcement of dietary sodium restriction, in
patients who have worsening hypertension due to high sodium intake.
*Rapidly lowering blood pressure below the autoregulatory range of an organ
system (most importantly the cerebral, renal, or coronary beds) can result in
reduced perfusion, leading to ischemia and infarction. It is usually
appropriate in these situations instead to gradually reduce blood pressure
over 24 to 48 hours.
Most patients with hypertensive urgency can be treated as outpatients.
*Untreated hypertension:
--The approach should take into consideration the individual patient's risk with
persistence of severe hypertension, the likely duration of severe hypertension, and of
cerebrovascular or myocardial ischemia with rapid reduction in blood pressure.
--Relatively rapid initial blood pressure reduction (over several hours): oral furosemide
(if the patient is not volume depleted) at a dose of 20 mg (or higher if the renal
function is not normal); a small dose of oral clonidine (0.2 mg); or a small dose of oral
captopril (6.25 or 12.5 mg) observed for a few hours, to ascertain a reduction in
blood pressure of 20 to 30 mmHg longer acting agent is prescribed and the patient is
sent home to follow up within a few days.
--Reduction over one to two days: Depending on the patient, a calcium channel blocker
(but not sublingual nifedipine), beta blocker or angiotensin converting enzyme (ACE)
inhibitor or receptor blocker can be started. Examples in these categories are oral
nifedipine 30 mg once daily (of the long-acting preparation), oral metoprolol XL 50 mg
daily, or ramipril 10 mg once daily. Some experts initiate therapy with two agents or a
combination agent, one of which is a thiazide diuretic. The rationale is that most
patients with blood pressure ≥20/10 mmHg above goal.
--Patients at high risk for cardiovascular events (eg, long-standing diabetes, known
coronary artery disease or prior stroke), should probably be admitted.
MECHANISMS OF VASCULAR INJURY
--With mild to moderate elevations in blood pressure, the initial response is
arterial and arteriolar vasoconstriction. This autoregulatory process both
maintains tissue perfusion at a relatively constant level and prevents the
increase in pressure from being transmitted to the smaller, more distal
vessels.
--With increasingly severe hypertension, however, autoregulation eventually
fails damage to the vascular wall. Disruption of the vascular endothelium
then allows plasma constituents (including fibrinoid material) to enter the
vascular wall, thereby narrowing or obliterating the vascular lumen. Within
the brain, the breakthrough vasodilation from failure of autoregulation leads
to the development of cerebral edema and the clinical picture of hypertensive
encephalopathy.
--The level at which fibrinoid necrosis occurs is dependent upon the baseline
BP.
CLINICAL MANIFESTATIONS
--Most often occurs in patients with long-standing uncontrolled hypertension, many of
whom have discontinued antihypertensive therapy. Underlying renal artery stenosis is
also commonly present.
--Marked elevation in BP.
--Retinal hemorrhages and exudates (representing both ischemic damage and leakage
of blood and plasma from affected vessels) and papilledema.
--Malignant nephrosclerosis, leading to acute kidney injury, hematuria, and
proteinuria. The renal vascular disease in this setting leads to glomerular ischemia and
activation of the renin-angiotensin system, possibly resulting in exacerbation of the
hypertension.
--Acute myocardial infarction, pulmonary edema, unstable angina, dissecting aortic
aneurysm, or eclampsia
--Neurologic symptoms due to intracerebral or subarachnoid bleeding, lacunar
infarcts, or hypertensive encephalopathy {insidious onset of headache, nausea, and
vomiting, followed by nonlocalizing neurologic symptoms such as
restlessness, confusion, and seizures and coma}
**Magnetic resonance imaging may reveal edema of the white matter of the parieto-
occipital regions, a finding termed reversible posterior leukoencephalopathy
syndrome. When the MRI reveals primarily pontine abnormalities, the condition has
been called hypertensive brainstem encephalopathy
--Initial goal of reducing mean arterial blood pressure by 10% to
15%, but no more than 25%, in the first hour and then, if stable, to a
goal of 160/100-110 mm Hg within the next 2 to 6 hours gradual
healing of the necrotizing vascular lesions.
--Aortic dissection is a special situation that requires
reduction of the systolic blood pressure to at least 120 mm Hg within
20 minutes.
--More aggressive hypotensive therapy is both unnecessary and may
reduce the blood pressure below the autoregulatory range, possibly
leading to ischemic events (such as stroke or coronary disease) .
--Then: switched to oral therapy, with the diastolic pressure being
gradually reduced to 85 to 90 mmHg over two to three months.
--Even with effective antihypertensive therapy, most patients who
have had malignant hypertension still have moderate to severe chronic
and acute vascular damage and are at continued risk for
coronary, cerebrovascular, and renal disease.
ANTIHYPERTENSIVE DRUGS
-- A slower onset of action and an inability to control the degree
of BP reduction has limited the use of oral antihypertensive
agents in the therapy of hypertensive crises.
--They may, however, be useful when there is no rapid access to
the parenteral medications described above. Both sublingual
nifedipine (10 mg) and sublingual captopril (25 mg) can
substantially lower the BP within 10 to 30 minutes in many
patients.
--The major risk with these drugs is ischemic symptoms
(eg, angina pectoris, myocardial infarction, or stroke) due to an
excessive and uncontrolled hypotensive response. Thus, their
use should generally be avoided in the treatment of hypertensive
crises if more controllable drugs are available.
Thank you

More Related Content

What's hot

Htn in ckd tarek
Htn in ckd tarekHtn in ckd tarek
Htn in ckd tarek
FarragBahbah
 
2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptx2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptx
subhankar16
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
Praveen Nagula
 
Hypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney DiseaseHypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney Disease
Ade Wijaya
 
Diabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 UpdateDiabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 Update
Christos Argyropoulos
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Dr. Aryan (Anish Dhakal)
 
Hypertension in special situation
Hypertension in special situationHypertension in special situation
Hypertension in special situation
Rashna Sharmin
 
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Chetan Ganteppanavar
 
Cardiorenal syndrome
Cardiorenal syndromeCardiorenal syndrome
Cardiorenal syndrome
Domina Petric
 
Secondary hypertension
Secondary hypertensionSecondary hypertension
Secondary hypertension
raj kumar
 
2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf
Meccar Moniem Elino
 
Guideline for the management of heart failure
Guideline for the management of heart failureGuideline for the management of heart failure
Guideline for the management of heart failure
Iqbal Dar
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates
Praveen Nagula
 
Hypertensive Emergencies
Hypertensive EmergenciesHypertensive Emergencies
Hypertensive Emergencies
Nahid Sherbini
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
Dr. Prem Mohan Jha
 
Refractory hypertension
Refractory hypertensionRefractory hypertension
Refractory hypertension
Ramachandra Barik
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
mondy19
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
dranjalivyas
 
Guideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEFGuideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEF
Kerolus Shehata
 
Hypertensive Emergencies
Hypertensive EmergenciesHypertensive Emergencies
Hypertensive Emergencies
Dokka Srinivasu
 

What's hot (20)

Htn in ckd tarek
Htn in ckd tarekHtn in ckd tarek
Htn in ckd tarek
 
2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptx2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptx
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Hypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney DiseaseHypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney Disease
 
Diabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 UpdateDiabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 Update
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
Hypertension in special situation
Hypertension in special situationHypertension in special situation
Hypertension in special situation
 
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
 
Cardiorenal syndrome
Cardiorenal syndromeCardiorenal syndrome
Cardiorenal syndrome
 
Secondary hypertension
Secondary hypertensionSecondary hypertension
Secondary hypertension
 
2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf
 
Guideline for the management of heart failure
Guideline for the management of heart failureGuideline for the management of heart failure
Guideline for the management of heart failure
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates
 
Hypertensive Emergencies
Hypertensive EmergenciesHypertensive Emergencies
Hypertensive Emergencies
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
 
Refractory hypertension
Refractory hypertensionRefractory hypertension
Refractory hypertension
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
 
Guideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEFGuideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEF
 
Hypertensive Emergencies
Hypertensive EmergenciesHypertensive Emergencies
Hypertensive Emergencies
 

Similar to Resistant hypertension

Resistant Hypertension.pptx
Resistant Hypertension.pptxResistant Hypertension.pptx
Resistant Hypertension.pptx
AbdirizakJacda
 
Hypertension
HypertensionHypertension
Hypertension
Dennis George
 
Refractory hypertension approach
Refractory hypertension approachRefractory hypertension approach
Refractory hypertension approach
Saikumar Dunga
 
Keycards Diuretics in Heart Failure.pdf
Keycards Diuretics in Heart Failure.pdfKeycards Diuretics in Heart Failure.pdf
Keycards Diuretics in Heart Failure.pdf
ElizaFattima1
 
Heart failure review
Heart failure reviewHeart failure review
Heart failure review
Vikas Gupta
 
furosemide + dapa.pptx
furosemide + dapa.pptxfurosemide + dapa.pptx
furosemide + dapa.pptx
manishchaudhary833009
 
Angiotensin neprilysin inhibition in acute decompensated heart failure
Angiotensin neprilysin inhibition in acute decompensated heart failureAngiotensin neprilysin inhibition in acute decompensated heart failure
Angiotensin neprilysin inhibition in acute decompensated heart failure
Shadab Ahmad
 
hypertension treatment update
hypertension treatment updatehypertension treatment update
hypertension treatment update
Basem Enany
 
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
Mohamed E. Elrggal
 
Nuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acutoNuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acuto
drucsamal
 
Chlorthalidone for poorly controlled hypertension in chronic kidney diseases
Chlorthalidone for poorly controlled hypertension in chronic kidney diseasesChlorthalidone for poorly controlled hypertension in chronic kidney diseases
Chlorthalidone for poorly controlled hypertension in chronic kidney diseases
Shadab Ahmad
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
Sahar Gamal
 
Af rate vs rhythm control.samir rafla 2
Af rate vs rhythm control.samir rafla 2Af rate vs rhythm control.samir rafla 2
Af rate vs rhythm control.samir rafla 2
Alexandria University, Egypt
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developments
Salutaria
 
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdfCognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
addi33
 
Resistant hypertension an approach to management - copied by samir rafla
Resistant hypertension  an approach to management - copied by samir raflaResistant hypertension  an approach to management - copied by samir rafla
Resistant hypertension an approach to management - copied by samir rafla
Alexandria University, Egypt
 
Journal club
Journal clubJournal club
Journal club
Priyanka Thakur
 
Recent Advancements in the treatment of Hypertension.
Recent Advancements  in the treatment of Hypertension.Recent Advancements  in the treatment of Hypertension.
Recent Advancements in the treatment of Hypertension.
Akshata Darandale
 
Hypertenson and IHD
Hypertenson and IHDHypertenson and IHD
Hypertenson and IHD
Soumya Nath Maiti
 
Djjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
DjjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjdDjjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
Djjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
ssuserdb48e4
 

Similar to Resistant hypertension (20)

Resistant Hypertension.pptx
Resistant Hypertension.pptxResistant Hypertension.pptx
Resistant Hypertension.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Refractory hypertension approach
Refractory hypertension approachRefractory hypertension approach
Refractory hypertension approach
 
Keycards Diuretics in Heart Failure.pdf
Keycards Diuretics in Heart Failure.pdfKeycards Diuretics in Heart Failure.pdf
Keycards Diuretics in Heart Failure.pdf
 
Heart failure review
Heart failure reviewHeart failure review
Heart failure review
 
furosemide + dapa.pptx
furosemide + dapa.pptxfurosemide + dapa.pptx
furosemide + dapa.pptx
 
Angiotensin neprilysin inhibition in acute decompensated heart failure
Angiotensin neprilysin inhibition in acute decompensated heart failureAngiotensin neprilysin inhibition in acute decompensated heart failure
Angiotensin neprilysin inhibition in acute decompensated heart failure
 
hypertension treatment update
hypertension treatment updatehypertension treatment update
hypertension treatment update
 
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
 
Nuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acutoNuove Prospective nel trattamento dello scompenso acuto
Nuove Prospective nel trattamento dello scompenso acuto
 
Chlorthalidone for poorly controlled hypertension in chronic kidney diseases
Chlorthalidone for poorly controlled hypertension in chronic kidney diseasesChlorthalidone for poorly controlled hypertension in chronic kidney diseases
Chlorthalidone for poorly controlled hypertension in chronic kidney diseases
 
Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
 
Af rate vs rhythm control.samir rafla 2
Af rate vs rhythm control.samir rafla 2Af rate vs rhythm control.samir rafla 2
Af rate vs rhythm control.samir rafla 2
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developments
 
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdfCognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
 
Resistant hypertension an approach to management - copied by samir rafla
Resistant hypertension  an approach to management - copied by samir raflaResistant hypertension  an approach to management - copied by samir rafla
Resistant hypertension an approach to management - copied by samir rafla
 
Journal club
Journal clubJournal club
Journal club
 
Recent Advancements in the treatment of Hypertension.
Recent Advancements  in the treatment of Hypertension.Recent Advancements  in the treatment of Hypertension.
Recent Advancements in the treatment of Hypertension.
 
Hypertenson and IHD
Hypertenson and IHDHypertenson and IHD
Hypertenson and IHD
 
Djjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
DjjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjdDjjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
Djjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjdjjddjdjd
 

More from Basem Enany

updated Preoperative assessment of noncardiac surgeries
updated Preoperative assessment of noncardiac surgeriesupdated Preoperative assessment of noncardiac surgeries
updated Preoperative assessment of noncardiac surgeries
Basem Enany
 
mitral regurgitation american guidlines 2014
mitral regurgitation american guidlines 2014mitral regurgitation american guidlines 2014
mitral regurgitation american guidlines 2014
Basem Enany
 
Myocardial infarction clinical picture, investigations European guidlines 2012
Myocardial infarction clinical picture, investigations European guidlines 2012Myocardial infarction clinical picture, investigations European guidlines 2012
Myocardial infarction clinical picture, investigations European guidlines 2012
Basem Enany
 
Acute Mitral regurge
Acute Mitral regurgeAcute Mitral regurge
Acute Mitral regurge
Basem Enany
 
Jugular venous pressure
Jugular venous pressureJugular venous pressure
Jugular venous pressure
Basem Enany
 
Infective endocarditis european guidlines 2012
Infective endocarditis european guidlines 2012Infective endocarditis european guidlines 2012
Infective endocarditis european guidlines 2012
Basem Enany
 
mitral stenosis AHA guidlines 2014
mitral stenosis AHA guidlines 2014mitral stenosis AHA guidlines 2014
mitral stenosis AHA guidlines 2014
Basem Enany
 
aortic regurge AHA guidlines 2014
aortic regurge AHA guidlines 2014aortic regurge AHA guidlines 2014
aortic regurge AHA guidlines 2014
Basem Enany
 
aortic stenosis AHA guidlines 2014
aortic stenosis AHA guidlines 2014aortic stenosis AHA guidlines 2014
aortic stenosis AHA guidlines 2014
Basem Enany
 
Preoperative hypertension
Preoperative hypertensionPreoperative hypertension
Preoperative hypertension
Basem Enany
 
Hypertension diagnosis
Hypertension diagnosisHypertension diagnosis
Hypertension diagnosis
Basem Enany
 
Heart failure treatment II european guidlines 2012
Heart failure treatment II european guidlines 2012Heart failure treatment II european guidlines 2012
Heart failure treatment II european guidlines 2012
Basem Enany
 
Heart failure treatment european guidlines 2012
Heart failure treatment european guidlines 2012Heart failure treatment european guidlines 2012
Heart failure treatment european guidlines 2012
Basem Enany
 
Heart failure pathophysiology
Heart failure pathophysiologyHeart failure pathophysiology
Heart failure pathophysiology
Basem Enany
 
Heart failure diagnosis: european guidlines 2012
Heart failure diagnosis: european guidlines 2012Heart failure diagnosis: european guidlines 2012
Heart failure diagnosis: european guidlines 2012
Basem Enany
 
Guidelines cardiac-pacing-slides
Guidelines cardiac-pacing-slidesGuidelines cardiac-pacing-slides
Guidelines cardiac-pacing-slides
Basem Enany
 
Examination of pulse
Examination of pulseExamination of pulse
Examination of pulse
Basem Enany
 
Cardiovascular diseases during pregnancy, european guidlines 2011
Cardiovascular diseases during pregnancy, european guidlines 2011Cardiovascular diseases during pregnancy, european guidlines 2011
Cardiovascular diseases during pregnancy, european guidlines 2011
Basem Enany
 
Chest pain differential diagnosis
Chest pain differential diagnosisChest pain differential diagnosis
Chest pain differential diagnosis
Basem Enany
 
acute Aortic regurge
acute Aortic regurgeacute Aortic regurge
acute Aortic regurge
Basem Enany
 

More from Basem Enany (20)

updated Preoperative assessment of noncardiac surgeries
updated Preoperative assessment of noncardiac surgeriesupdated Preoperative assessment of noncardiac surgeries
updated Preoperative assessment of noncardiac surgeries
 
mitral regurgitation american guidlines 2014
mitral regurgitation american guidlines 2014mitral regurgitation american guidlines 2014
mitral regurgitation american guidlines 2014
 
Myocardial infarction clinical picture, investigations European guidlines 2012
Myocardial infarction clinical picture, investigations European guidlines 2012Myocardial infarction clinical picture, investigations European guidlines 2012
Myocardial infarction clinical picture, investigations European guidlines 2012
 
Acute Mitral regurge
Acute Mitral regurgeAcute Mitral regurge
Acute Mitral regurge
 
Jugular venous pressure
Jugular venous pressureJugular venous pressure
Jugular venous pressure
 
Infective endocarditis european guidlines 2012
Infective endocarditis european guidlines 2012Infective endocarditis european guidlines 2012
Infective endocarditis european guidlines 2012
 
mitral stenosis AHA guidlines 2014
mitral stenosis AHA guidlines 2014mitral stenosis AHA guidlines 2014
mitral stenosis AHA guidlines 2014
 
aortic regurge AHA guidlines 2014
aortic regurge AHA guidlines 2014aortic regurge AHA guidlines 2014
aortic regurge AHA guidlines 2014
 
aortic stenosis AHA guidlines 2014
aortic stenosis AHA guidlines 2014aortic stenosis AHA guidlines 2014
aortic stenosis AHA guidlines 2014
 
Preoperative hypertension
Preoperative hypertensionPreoperative hypertension
Preoperative hypertension
 
Hypertension diagnosis
Hypertension diagnosisHypertension diagnosis
Hypertension diagnosis
 
Heart failure treatment II european guidlines 2012
Heart failure treatment II european guidlines 2012Heart failure treatment II european guidlines 2012
Heart failure treatment II european guidlines 2012
 
Heart failure treatment european guidlines 2012
Heart failure treatment european guidlines 2012Heart failure treatment european guidlines 2012
Heart failure treatment european guidlines 2012
 
Heart failure pathophysiology
Heart failure pathophysiologyHeart failure pathophysiology
Heart failure pathophysiology
 
Heart failure diagnosis: european guidlines 2012
Heart failure diagnosis: european guidlines 2012Heart failure diagnosis: european guidlines 2012
Heart failure diagnosis: european guidlines 2012
 
Guidelines cardiac-pacing-slides
Guidelines cardiac-pacing-slidesGuidelines cardiac-pacing-slides
Guidelines cardiac-pacing-slides
 
Examination of pulse
Examination of pulseExamination of pulse
Examination of pulse
 
Cardiovascular diseases during pregnancy, european guidlines 2011
Cardiovascular diseases during pregnancy, european guidlines 2011Cardiovascular diseases during pregnancy, european guidlines 2011
Cardiovascular diseases during pregnancy, european guidlines 2011
 
Chest pain differential diagnosis
Chest pain differential diagnosisChest pain differential diagnosis
Chest pain differential diagnosis
 
acute Aortic regurge
acute Aortic regurgeacute Aortic regurge
acute Aortic regurge
 

Recently uploaded

Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
chandankumarsmartiso
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 

Recently uploaded (20)

Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 

Resistant hypertension

  • 1. D . B A S E M E L S A I D E N A N Y L E C T U R E R O F C A R D I O L O G Y A I N S H A M S U N I V E R S I T Y Resistant Hypertension: Treatment
  • 2. Resistant hypertension --Definition: 2008 American Heart Association guideline  blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes, one of which should be a diuretic. Patients whose blood pressure is controlled with four or more medications are considered to have resistant hypertension (20-30%).
  • 3. Treatment of resistant hypertension 1-Identify and treat secondary hypertension. 2-Stop medications that raise the blood pressure (next slide). 3-Out-of-office BP monitoring: Apparently resistant patients should be evaluated by out-of office blood pressure measurements, either by self measurement of blood pressure at home or by ambulatory monitoring. Both home and ambulatory blood pressure measurements help to identify white coat hypertension. 4-NONPHARMACOLOGIC THERAPY 5-PHARMACOLOGIC THERAPY
  • 4. - Nonnarcotic analgesics - Nonsteroidal antiinflammatory agents, including aspirin - Selective COX-2 inhibitors - Sympathomimetic agents (decongestants, diet pills, cocaine) - Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, a mphetamine, methamphetamine, modafinil) - Alcohol - Oral contraceptives - Cyclosporine - Erythropoietin - Natural licorice - Herbal compounds (ephedra or ma huang)
  • 5. Diuretics --Persistent volume expansion (typically not sufficient to produce edema) contributes to resistant hypertension, even among patients who have been on conventional doses of thiazide diuretics. Serum brain-type natriuretic peptide and atrial natriuretic peptide levels are significantly higher, suggesting volume expansion. --Diuretics should be titrated until the blood pressure goal or the maximum recommended dose has been reached or the patient has signs suggestive of overdiuresis such as fatigue, orthostatic hypotension, or decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the serum creatinine concentration. --In those with little renal impairment, chlorthalidone is preferred to hydrochlorothiazide for the treatment of resistant hypertension. --Begin chlorthalidone at 12.5 mg daily, which requires splitting of the 25 mg pill, with subsequent titration up to 25 mg daily or, rarely, higher. {serum K}
  • 6. --Among patients with an estimated glomerular filtration rate of less than 30 mL/min per m2, thiazide diuretics are less effective and loop diuretics, such as furosemide, torsemide, or bumetanide, may be necessary for effective volume control. Furosemide is relatively short acting and usually requires at least twice daily dosing. A loop diuretic with a longer duration of action and more consistent absorption, such as torsemide, may be more effective
  • 7. Aldosterone antagonists --Spironolactone, eplerenone, and amiloride provide significant antihypertensive benefit when added to existing multiple drug regimens in patients with resistant hypertension .{significantly higher plasma aldosterone levels in patients with resistant hypertension compared with individuals who have normal blood pressure or controlled hypertension } --Spironolactone may be more likely to cause hyperkalemia in patients with chronic kidney disease .
  • 8. CHOICE OF REGIMEN --The triple combination of an ACE inhibitor or ARB, a long- acting dihydropyridine calcium channel blocker (usually amlodipine), and a long-acting thiazide diuretic (preferably chlorthalidone) is often effective and generally well tolerated. --Uncontrolled with such a three drug regimen at maximum recommended and tolerated doses spironolactone: 12.5 mg/day (which requires splitting of a 25 mg tablet) before titrating to 25 and, if necessary, 50 mg/day. The risk of adverse effects such as gynecomastia, breast tenderness, and erectile dysfunction increases with higher doses. [eplerenone, is now generic and does not induce the side effects seen with spironolactone]
  • 9. --Some patients with resistant hypertension are being treated with a three drug regimen different: If the patient is on hydrochlorothiazide, switch to chlorthalidone. If the current regimen includes a drug not from the three recommended drug classes, add the missing preferred drug and assess the response. Do not discontinue any drugs, as long as they are well tolerated, before achieving blood pressure control. --If the patient is still hypertensive, additional medications are added sequentially. Possible agents that may be used include vasodilating beta blockers (labetalol, carvedilol, or nebivolol), centrally acting agents (clonidine or guanfacine)[may be effective, but adverse effects are common], and direct vasodilators (hydralazine or minoxidil) [Fluid retention and tachycardia are common side effects. Minoxidil also causes hirsutism, which may be a particular problem in women that may require switching to hydralazine(lupus like=withdrawal, nausea, vomiting, flushing,tachycardia), and pericarditis].
  • 10. Catheter-based radiofrequency ablation of renal sympathetic nerves The mechanism by which renal sympathetic denervation improves management of BP is complex and involves the following factors: -Decreasing efferent sympathetic signaling to kidneys -Reducing norepinephrine spillover -Natriuresis -Increasing renal blood flow -Lowering plasma rennin activity -Decreasing renal afferent signalling and central sympathetic activation
  • 11.
  • 12. Indications --Refractory hypertension with office SBP >160 mmHg despite treatment with the least 3 antihypertensive medications including diuretic in optimal doses. --Exclusion of secondary forms of hypertension. --Exclusion of “white coat” hypertension using ambulatory blood pressure monitoring.
  • 13.
  • 14. SYMPLICITY HTN-3: Renal Denervation Fails to Reduce BP in Resistant-Hypertension Patients Led by Dr Deepak Bhatt (Brigham and Women's Hospital, Boston, MA) and Dr George Bakris (University of Chicago, IL), SYMPLICITY HTN-3 is a randomized, sham-controlled renal-denervation study in 535 patients with severe resistant hypertension. After six months, the mean change in systolic blood pressure was a reduction of 14.13 mm Hg in the renal-denervation arm and 11.74 mm Hg in the sham-controlled arm, a difference of 2.39 mm Hg that was not statistically significant. Regarding the change in the 24-hour ambulatory systolic blood pressure, the reduction at six months was 6.75 mm Hg in the renal-denervation arm and 4.79 mm Hg in the control arm, a difference of 1.96 mm Hg that was also not statistically
  • 15. For anyone who participates in clinical trials, the oversight of a clinical trial is such that the patients are very rigorously followed, and there is pill-counting and recommendations for strict compliance, all of which is very different from what happens with "optimal medical therapy" in real-world practice. Furthermore, this was a renal denervation strategy with a particular device, so it could be that this particular device isn't the best device for renal denervation. A third practical question, which is unanswered, is whether we really achieved renal denervation. The animal and preclinical trials looked at how much energy was needed to create an injury that went from the renal artery lumen down to the renal nerves. Perhaps in this middle- aged group of patients with hypertension on a western diet, there is greater thickening of the renal vessel, which could actually cause problems in delivering the energy required to achieve effective renal denervation.
  • 16.
  • 17. Contraindications --Increased bleeding risk (bleeding diathesis, thrombocytopenia, severe anemia) --Chronic renal disease --eGFR < 45 mL/min/1.73m2 --Type 1 diabetes --Previous renal artery intervention (angioplasty, stent implantation) --Anatomic abnormalities and variants of renal artery including aneurysms, severe stenosis, reference diameter <4 mm, excessive tortuosity, aortic aneurysm --Age < 18 years --Pregnancy
  • 18. Technique --Vascular access is similar to renal angiography and angioplasty. --Current 5F system uses 6F guide catheters. After engaging the renal artery, and angiography to evaluate the anatomy of the renal arteries, the ablation catheter is placed under fluoroscopic guidance in the distal segment of the renal artery. --Each RF application is followed by retraction by at least 5 mm and rotation by 90 degrees of the catheter tip, from the first distal main renal artery bifurcation to the ostium. --To achieve complete denervation, multiple (4-6) RF applications are used depending on the length of the trunk of both renal arteries. This approach provides circumferential disruption of sympathetic nerves. --The procedure is performed under analgetic or conscious sedation to lessen the pain
  • 19. Symplicity Catheter System Design (Medtronic Vascular)
  • 20. **Procedure-related complications are: -Access site complication (hematoma, pseudoaneurysm, dissection) -Renal artery dissection -Progression of a pre-existing renal artery stenosis -Regeneration of efferent nerves leading to relapse of resistant hypertension -Bradycardia
  • 21. --Was tested in the Symplicity-HTN-2 trial of 106 patients with resistant hypertension despite treatment with an average of five antihypertensive medications including a diuretic. --The patients were randomly assigned to renal sympathetic denervation or maintenance of previous medical therapy. --At six months, radiofrequency ablation significantly decreased the office blood pressure from 178/97 to 143/85 mmHg compared with no decrease in blood pressure in patients maintained on baseline antihypertensive therapy. --In addition, a systolic pressure of less than 140 mmHg was attained significantly more often with radiofrequency ablation (39 versus 6 %). --There was no significant difference between the groups in kidney function. Complications related to radiofrequency ablation included one femoral artery pseudoaneurysm. --Long-term data regarding efficacy and safety of radiofrequency ablation remain limited.
  • 22. Possible indications 1-Sleep apnea: The mechanism of such effect of renal denervation of sleep apnea is unknown, however the influence on sodium retention and volemic status is likely to be involved. 2-Insulin Resistance/type 2 diabetes mellitus: The beneficial effects on glucose metabolism may be explained by several effects of renal denervation: inhibition of central sympathetic tone, reduced release of norepinephrine, better perfusion of skeletal muscles mediated via a decrease of alpha- adrenergic tone leading to increased glucose uptake. 3-Congestive Heart Failure: Increased sympathetic activity is present in patients with heart failure and it is correlated with functional class.
  • 23. Electrical stimulation of carotid sinus baroreceptors --Electrical stimulation of the carotid sinus baroreflex system, or baroreflex activation therapy (BAT), may decrease blood pressure in patients with resistant hypertension. --Three feasibility studies have shown reductions in blood pressure after implantation of a device designed to stimulate the carotid baroreflex system .
  • 24. *In the Rheos Pivotal Trial, 265 patients with resistant hypertension underwent surgical implantation of a device designed to stimulate the carotid baroreceptors. One month after surgery, patients were randomly assigned to have BAT turned on immediately or to have BAT turned on six months later. The patients were followed for at least 12 months: --At six months, patients receiving BAT had a nonsignificantly larger decrease in systolic pressure (16 versus 9 mmHg) and a nonsignificantly greater likelihood of having a 10 mmHg or larger decrease in systolic pressure (54 versus 46 %). In addition, patients receiving BAT were significantly more likely to achieve a goal systolic pressure of 140 mmHg or lower (42 versus 24 %). --At twelve months, the mean reduction in systolic pressure in the BAT group was 25 mmHg; more than 80 % of these patients had at least a 10 mmHg decrease in systolic pressure. --Within one month of surgery, 35 % of patients had a serious procedure-related adverse event, including nerve injury. In most patients, procedure-related adverse events resolved spontaneously. Seven patients died (3 %), but none were attributable to the device.
  • 25. *Malignant hypertension: --Refers to marked hypertension with retinal hemorrhages, exudates, or papilledema. These findings may be associated with hypertensive encephalopathy{cerebral oedema}. --Usually associated with BP>180/120 mmHg. However, it can occur at diastolic pressures as low as 100 mmHg in previously normotensive patients with acute hypertension due to preeclampsia or acute glomerulonephritis. *Hypertensive urgency: --Severe hypertension (as defined by a diastolic blood pressure above 120 mmHg) in asymptomatic patients. --There is no proven benefit from rapid reduction in BP in asymptomatic patients who have no evidence of acute end-organ damage and are at little short-term risk.
  • 26. Hypertensive urgencies *BP>180/120mmHg, no symptoms apart from headache. *A relatively rapid reduction in blood pressure (BP) was recommended in the past. However, in the absence of symptoms a more gradual reduction in pressure is suggested. *While a variety of oral therapeutic modalities have been used, including clonidine, sublingual nifedipine, and oral or sublingual captopril, sublingual nifedipine is now contraindicated in this setting {blood pressure falls below the range at which tissue perfusion can be maintained by autoregulation}.
  • 27. *All patients should be provided a quiet room to rest; this can lead to a fall in BP of 10 to 20 mmHg or more. *Previously treated hypertension: --Increase the dose of existing antihypertensive medications, or add another agent. --Reinstitution of medications in non-adherent patients. --Addition of a diuretic, and reinforcement of dietary sodium restriction, in patients who have worsening hypertension due to high sodium intake. *Rapidly lowering blood pressure below the autoregulatory range of an organ system (most importantly the cerebral, renal, or coronary beds) can result in reduced perfusion, leading to ischemia and infarction. It is usually appropriate in these situations instead to gradually reduce blood pressure over 24 to 48 hours. Most patients with hypertensive urgency can be treated as outpatients.
  • 28. *Untreated hypertension: --The approach should take into consideration the individual patient's risk with persistence of severe hypertension, the likely duration of severe hypertension, and of cerebrovascular or myocardial ischemia with rapid reduction in blood pressure. --Relatively rapid initial blood pressure reduction (over several hours): oral furosemide (if the patient is not volume depleted) at a dose of 20 mg (or higher if the renal function is not normal); a small dose of oral clonidine (0.2 mg); or a small dose of oral captopril (6.25 or 12.5 mg) observed for a few hours, to ascertain a reduction in blood pressure of 20 to 30 mmHg longer acting agent is prescribed and the patient is sent home to follow up within a few days. --Reduction over one to two days: Depending on the patient, a calcium channel blocker (but not sublingual nifedipine), beta blocker or angiotensin converting enzyme (ACE) inhibitor or receptor blocker can be started. Examples in these categories are oral nifedipine 30 mg once daily (of the long-acting preparation), oral metoprolol XL 50 mg daily, or ramipril 10 mg once daily. Some experts initiate therapy with two agents or a combination agent, one of which is a thiazide diuretic. The rationale is that most patients with blood pressure ≥20/10 mmHg above goal. --Patients at high risk for cardiovascular events (eg, long-standing diabetes, known coronary artery disease or prior stroke), should probably be admitted.
  • 29. MECHANISMS OF VASCULAR INJURY --With mild to moderate elevations in blood pressure, the initial response is arterial and arteriolar vasoconstriction. This autoregulatory process both maintains tissue perfusion at a relatively constant level and prevents the increase in pressure from being transmitted to the smaller, more distal vessels. --With increasingly severe hypertension, however, autoregulation eventually fails damage to the vascular wall. Disruption of the vascular endothelium then allows plasma constituents (including fibrinoid material) to enter the vascular wall, thereby narrowing or obliterating the vascular lumen. Within the brain, the breakthrough vasodilation from failure of autoregulation leads to the development of cerebral edema and the clinical picture of hypertensive encephalopathy. --The level at which fibrinoid necrosis occurs is dependent upon the baseline BP.
  • 30. CLINICAL MANIFESTATIONS --Most often occurs in patients with long-standing uncontrolled hypertension, many of whom have discontinued antihypertensive therapy. Underlying renal artery stenosis is also commonly present. --Marked elevation in BP. --Retinal hemorrhages and exudates (representing both ischemic damage and leakage of blood and plasma from affected vessels) and papilledema. --Malignant nephrosclerosis, leading to acute kidney injury, hematuria, and proteinuria. The renal vascular disease in this setting leads to glomerular ischemia and activation of the renin-angiotensin system, possibly resulting in exacerbation of the hypertension. --Acute myocardial infarction, pulmonary edema, unstable angina, dissecting aortic aneurysm, or eclampsia --Neurologic symptoms due to intracerebral or subarachnoid bleeding, lacunar infarcts, or hypertensive encephalopathy {insidious onset of headache, nausea, and vomiting, followed by nonlocalizing neurologic symptoms such as restlessness, confusion, and seizures and coma} **Magnetic resonance imaging may reveal edema of the white matter of the parieto- occipital regions, a finding termed reversible posterior leukoencephalopathy syndrome. When the MRI reveals primarily pontine abnormalities, the condition has been called hypertensive brainstem encephalopathy
  • 31. --Initial goal of reducing mean arterial blood pressure by 10% to 15%, but no more than 25%, in the first hour and then, if stable, to a goal of 160/100-110 mm Hg within the next 2 to 6 hours gradual healing of the necrotizing vascular lesions. --Aortic dissection is a special situation that requires reduction of the systolic blood pressure to at least 120 mm Hg within 20 minutes. --More aggressive hypotensive therapy is both unnecessary and may reduce the blood pressure below the autoregulatory range, possibly leading to ischemic events (such as stroke or coronary disease) . --Then: switched to oral therapy, with the diastolic pressure being gradually reduced to 85 to 90 mmHg over two to three months. --Even with effective antihypertensive therapy, most patients who have had malignant hypertension still have moderate to severe chronic and acute vascular damage and are at continued risk for coronary, cerebrovascular, and renal disease.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38. -- A slower onset of action and an inability to control the degree of BP reduction has limited the use of oral antihypertensive agents in the therapy of hypertensive crises. --They may, however, be useful when there is no rapid access to the parenteral medications described above. Both sublingual nifedipine (10 mg) and sublingual captopril (25 mg) can substantially lower the BP within 10 to 30 minutes in many patients. --The major risk with these drugs is ischemic symptoms (eg, angina pectoris, myocardial infarction, or stroke) due to an excessive and uncontrolled hypotensive response. Thus, their use should generally be avoided in the treatment of hypertensive crises if more controllable drugs are available.

Editor's Notes

  1. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)